You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信立泰(002294.SZ):子公司的特立帕肽注射液(欣復泰Pro®)獲批上市
格隆匯 04-21 16:29

格隆匯4月21日丨信立泰(002294.SZ)公佈,近日,深圳信立泰藥業股份有限公司子公司信立泰(蘇州)藥業有限公司收到國家藥品監督管理局核准簽發的“特立帕肽注射液”(欣復泰Pro®)藥品註冊證書。

“特立帕肽注射液”(欣復泰Pro®)主要用於有骨折高發風險的絕經後婦女骨質疏鬆症的治療,該產品為每天一次,注射前無需溶解,更方便患者使用。上市後,將進一步豐富公司骨科產品管線,並藉助欣復泰®(注射用重組特立帕肽)在骨科領域初步建立的良好市場基礎,為患者提供更多用藥選擇。

特立帕肽是國內唯一批准上市的促骨形成類抗骨松藥物,能夠有效改善骨微結構、增加骨強度,同時能促進骨癒合,降低椎體和非椎體骨折風險,是治療骨質疏鬆症的理想藥物之一,獲得國內外指南推薦。特立帕肽原研為禮來公司,2002年獲批在美國上市,2011年獲批在國內銷售。隨着人口老齡化加劇,醫保體系覆蓋的逐步健全和居民支付能力的提升,我國骨質疏鬆藥物存在較大的市場潛力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account